CTLA4 and neoplasm: In consistent with our mechanistic findings, immunofluorescence and flow cytometric analysis showed that mono‐Sunitinib or Sunitinib plus CTLA‐4 mAb treatment significantly decreased PD‐L1 level, increased CD8+ CTL population, and enhanced their activity in the tumor region of immune competent mice (Figure 6K–M and Figure S6C–E, Supporting Information).